Webinar

Large B cell lymphoma microenvironment archetype profiles

Now available to watch on demand.

Join us for this webinar featuring work from researchers at The University of Texas MD Anderson Cancer Center that identifies key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy.

B cell lymphomas (LBCL) are clinically and biologically heterogeneous lymphoid malignancies with complex microenvironments that are central to disease etiology. Here, Dr. Green's laboratory has employed single-nucleus multiome profiling of 232 tumor and control biopsies to characterize diverse cell types and subsets that are present in LBCL tumors, effectively capturing the lymphoid, myeloid, and non-hematopoietic cell compartments.

Cell subsets co-occurred in stereotypical lymphoma microenvironment archetype profiles (LymphoMAPs) defined by:

• A sparsity of T cells and high frequencies of cancer-associated fibroblasts and tumor-associated macrophages (FMAC)
• Lymph node architectural cell types with naive and memory T cells (LN)
• Activated macrophages and exhausted CD8+ T cells (TEX). Divergent patterns of cell-cell communication underpinned the transcriptional phenotypes of archetype-defining cell subsets resulting in exclusion, support, or suppression of T cells, respectively.

Consistent with this, LymphoMAPs were associated with significantly different clinical outcomes following CD19 chimeric antigen receptor (CAR) T cell therapy.

Featuring

Michael Green, PhD

Vice Chair for Research
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center